BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Huang CH, Amodio P. Can rifaximin for hepatic encephalopathy be discontinued during broad-spectrum antibiotic treatment? World J Hepatol 2024; 16(2): 115-119 [PMID: 38495281 DOI: 10.4254/wjh.v16.i2.115]
URL: https://www.wjgnet.com/1948-5182/full/v16/i2/115.htm
Number Citing Articles
1
Jie Cheng, Guo-Xin Sun, Li-Ying Cai, Qi-Qun Tang. Exploring pathogenic mechanism and nutritional treatment strategies for hepatic encephalopathy based on the gut-liver axis theoryWorld Chinese Journal of Digestology 2024; 32(11): 793 doi: 10.11569/wcjd.v32.i11.793
Abstract() |  Core Tip() |  Full Article(HTML)() | Times Cited  (0) | Total Visits (0) | Open
2
Hideto Kawaratani, Tadashi Namisaki, Yasuteru Kondo, Ryoji Tatsumi, Naoto Kawabe, Norikazu Tanabe, Akira Sakamaki, Kyoko Hoshikawa, Yoshihito Uchida, Kei Endo, Takumi Kawaguchi, Tsunekazu Oikawa, Yoji Ishizu, Shuhei Hige, Taro Takami, Shuji Terai, Yoshiyuki Ueno, Satoshi Mochida, Kazuhiko Koike, Hitoshi Yoshiji. Real-World Setting of Efficacy and Safety of 3 Years of Rifaximin Administration in Japanese Patients with Hepatic Encephalopathy: A Multicenter Retrospective StudyJournal of Clinical Medicine 2025; 14(4): 1358 doi: 10.3390/jcm14041358
3
Elena Fasniuc-Pereu, Elena Niculina Drăgoi, Dumitru Bulgariu, Maria-Cristina Popescu, Laura Bulgariu. Removal of Rifampicin and Rifaximin Antibiotics on PET Fibers: Optimization, Modeling, and Mechanism InsightPolymers 2025; 17(15): 2089 doi: 10.3390/polym17152089